This biotech stock has plummeted over the past year. RBC says it sees a big gain ahead
- Posted on January 21, 2026
- By CNBC
- 2 Views
This biotech stock has plummeted over the past year. RBC says it sees a big gain ahead
RBC's $22 price target implies an upside of 74% for shares of Biohaven.
